Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Fareston
Fareston 60 mg tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-085591 · Präparat HOS-083163
An additive effect on QT interval prolongation between Fareston and the following drugs and other
medicinal products that may prolong the QTc interval cannot be excluded. This might lead to an
increased risk of ventricular arrhythmias, including Torsade de pointes. Therefore co-administration
of Fareston with any of the following medicinal products is contraindicated (see also section 4.3):
- antiarrhythmics class IA (e.g. quinidine, hydroquinidine, disopyramide)
- antiarrhythmics class III (e.g. amiodarone, sotalol, dofetilide, ibutilide)
- neuroleptics (e.g. phenothiazines, pimozide, sertindole, haloperidol, sultopride)
- certain antimicrobials agents (moxifloxacin, erythromycin IV, pentamidine, antimalarials
particularly halofantrine)
- certain antihistaminics (terfenadine, astemizole, mizolastine)
- others (cisapride, vincamine IV, bepridil, diphemanil).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) sotalol (HOS-085597) cisapride (HOS-085610) bepridil (HOS-085612) dofetilide (HOS-085598) halofantrine (HOS-085606) ibutilide (HOS-085599) quinidine (HOS-085593) hydroquinidine (HOS-085594) sultopride (HOS-085603) lead (HOS-085592) disopyramide (HOS-085595) diphemanil (HOS-085613) pimozide (HOS-085600) erythromycin (HOS-084514) moxifloxacin (HOS-085604) astemizole (HOS-085608) pentamidine (HOS-085605) haloperidol (HOS-085602) amiodarone (HOS-085596) terfenadine (HOS-085607) vincamine (HOS-085611) mizolastine (HOS-085609)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-30T12:24:00Z · SHA-256 3b25a11bbd424fca19782652cfc8662dd4db79f69f35943c40313fed13e66e0e · Passage 9429395d1b572fb000ebac0968a84f8f195781287110169960c945b4772df6c6 · Zeichen 0–900 im Abschnitt
Gegenanzeigen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.3 · PDF-Seite 4
HOS-086138 · Präparat HOS-083284
Concomitant medicinal product levels increased or decreased
1-Adrenoreceptor Alfuzosin Increased plasma concentrations of alfuzosin
Antagonist which may lead to severe hypotension (see
section 4.5).
Analgesics Pethidine, Increased plasma concentrations of
propoxyphene norpethidine and propoxyphene. Thereby,
increasing the risk of serious respiratory
depression or haematologic abnormalities, or
other serious adverse effects from these agents.
Antianginal Ranolazine Increased plasma concentrations of ranolazine
which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Anticancer Neratinib Increased plasma concentrations of neratinib
which may increase the potential for serious
and/or life-threatening reactions including
hepatotoxicity (see section 4.5).
Venetoclax Increased plasma concentrations of venetoclax.
Increased risk of tumor lysis syndrome at the
dose initiation and during the dose-titration
phase (see section 4.5).
Antiarrhythmics Amiodarone, bepridil, Increased plasma concentrations of amiodarone,
dronedarone, bepridil, dronedarone, encainide, flecanide,
encainide, flecanide, propafenone, quinidine. Thereby, increasing the
propafenone, quinidine risk of arrhythmias or other serious adverse
reactions from these agents.
Antibiotic Fusidic Acid Increased plasma concentrations of fusidic acid
and ritonavir.
Anti-gout Colchicine Potential for serious and/or life-threatening
reactions in patients with renal and/or hepatic
impairment (see sections 4.4 and 4.5).
Antihistamines Astemizole, Increased plasma concentrations of astemizole
terfenadine and terfenadine. Thereby, increasing the risk of
serious arrhythmias from these agents.
Antipsychotics/ Lurasidone Increased plasma concentrations of lurasidone
Neuroleptics which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Clozapine, pimozide Increased plasma concentrations of clozapine
and pimozide. Thereby, increasing the risk of
serious haematologic abnormalities, or other
serious adverse effects from these agents.
Quetiapine Increased plasma concentrations of quetiapine
which may lead to coma. The concomitant
administration with quetiapine is
contraindicated (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propoxyphene (HOS-086140) quetiapine (HOS-086150) encainide (HOS-086145) alfuzosin (HOS-086139) propafenone (HOS-084530) dronedarone (HOS-086144) fusidic acid (HOS-086146) bepridil (HOS-085612) quinidine (HOS-085593) neratinib (HOS-086142) venetoclax (HOS-086143) lead (HOS-085592) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) clozapine (HOS-086149) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ranolazine (HOS-086141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage f9fe97979894eedcce9660008265f9fc818cdb3984974bb2555b6c5e5869e4e5 · Zeichen 902–5292 im Abschnitt
Gegenanzeigen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 35–36
HOS-086388 · Präparat HOS-083284
35
Analgesics Pethidine, Increased plasma concentrations of
propoxyphene norpethidine and propoxyphene. Thereby,
increasing the risk of serious respiratory
depression or haematologic abnormalities, or
other serious adverse effects from these agents.
Antianginal Ranolazine Increased plasma concentrations of ranolazine
which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Anticancer Neratinib Increased plasma concentrations of neratinib
which may increase the potential for serious
and/or life-threatening reactions including
hepatotoxicity (see section 4.5).
Venetoclax Increased plasma concentrations of venetoclax.
Increased risk of tumor lysis syndrome at the
dose initiation and during the dose-titration
phase (see section 4.5).
Antiarrhythmics Amiodarone, bepridil, Increased plasma concentrations of amiodarone,
dronedarone, bepridil, dronedarone, encainide, flecainide,
encainide, flecainide, propafenone, quinidine. Thereby, increasing
propafenone, quinidine the risk of arrhythmias or other serious adverse
effects from these agents.
Antibiotic Fusidic Acid Increased plasma concentrations of fusidic acid
and ritonavir.
Antihistamines Astemizole, Increased plasma concentrations of astemizole
terfenadine and terfenadine. Thereby, increasing the risk of
serious arrhythmias from these agents.
Anti-gout Colchicine Potential for serious and/or life-threatening
reactions in patients with renal and/or hepatic
impairment (see sections 4.4 and 4.5).
Antipsychotics/ Lurasidone Increased plasma concentrations of lurasidone
Neuroleptics which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Clozapine, pimozide Increased plasma concentrations of clozapine
and pimozide. Thereby, increasing the risk of
serious haematologic abnormalities, or other
serious adverse effects from these agents.
Quetiapine Increased plasma concentrations of quetiapine
which may lead to coma. The concomitant
administration with quetiapine is
contraindicated (see section 4.5).
Ergot Derivatives Dihydroergotamine, Increased plasma concentrations of ergot
ergonovine, derivatives leading to acute ergot toxicity,
ergotamine, including vasospasm and ischaemia.
methylergonovine
GI motility agent Cisapride Increased plasma concentrations of cisapride.
Thereby, increasing the risk of serious
arrhythmias from this agent.
Lipid-modifying agents
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propoxyphene (HOS-086140) quetiapine (HOS-086150) encainide (HOS-086145) methylergonovine (HOS-086155) propafenone (HOS-084530) dronedarone (HOS-086144) cisapride (HOS-085610) fusidic acid (HOS-086146) flecainide (HOS-086203) bepridil (HOS-085612) quinidine (HOS-085593) neratinib (HOS-086142) venetoclax (HOS-086143) lead (HOS-085592) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) clozapine (HOS-086149) ergotamine (HOS-086154) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ranolazine (HOS-086141) ergonovine (HOS-086153) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage f76b82bf2af9e33f5778d35af3ff4a8ea2ea8d392666af7950204db67ec4ac88 · Zeichen 1234–5743 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 13
HOS-086202 · Präparat HOS-083284
Antiarrthymics
Amiodarone, bepridil, dronedarone, Ritonavir co-administration is likely to result in increased plasma concentrations of
encainide, flecainide, propafenone, amiodarone, bepridil, dronedarone, encainide, flecainide, propafenone, and
quinidine quinidine and is therefore contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): encainide (HOS-086145) propafenone (HOS-084530) dronedarone (HOS-086144) flecainide (HOS-086203) bepridil (HOS-085612) quinidine (HOS-085593) amiodarone (HOS-085596)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage db989a5b246ebda2c8effcb5a867688ba67111b2e2655b4b99403e29644def39 · Zeichen 13636–13987 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 45
HOS-086412 · Präparat HOS-083284
Antiarrthymics
Amiodarone, bepridil, dronedarone, Ritonavir co-administration is likely to result in increased plasma concentrations of
encainide, flecainide, propafenone, amiodarone, bepridil, dronedarone, encainide, flecainide, propafenone, and quinidine and
quinidine is therefore contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): encainide (HOS-086145) propafenone (HOS-084530) dronedarone (HOS-086144) flecainide (HOS-086203) bepridil (HOS-085612) quinidine (HOS-085593) amiodarone (HOS-085596)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 7be5a56d7eb28c6b0b362a7de5830a5d2ee65bd16f89e27afb151c7f671bb104 · Zeichen 13898–14249 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 12–13
HOS-108863 · Präparat HOS-093083
12
CYP3A4 inhibition by concomitantly administered with
lopinavir/ritonavir. Kaletra.
Antianginal
Ranolazine Due to CYP3A inhibition by The concomitant administration of
lopinavir/ritonavir, concentrations Kaletra and ranolazine is
of ranolazine are expected to contraindicated (see section 4.3).
increase.
Antiarrhythmics
Amiodarone, Dronedarone Amiodarone, Dronedarone: Concomitant administration of
Concentrations may be increased Kaletra and amiodarone or
due to CYP3A4 inhibition by dronedarone is contraindicated (see
lopinavir/ritonavir. section 4.3) as the risk of
arrhythmias or other serious
adverse reactions may be
increased.
Digoxin Digoxin: Caution is warranted and
Plasma concentrations may be therapeutic drug monitoring of
increased due to P-glycoprotein digoxin concentrations, if
inhibition by lopinavir/ritonavir. available, is recommended in case
The increased digoxin level may of co-administration of Kaletra and
lessen over time as P-gp digoxin. Particular caution should
induction develops. be used when prescribing Kaletra
in patients taking digoxin as the
acute inhibitory effect of ritonavir
on P-gp is expected to significantly
increase digoxin levels. Initiation
of digoxin in patients already
taking Kaletra is likely to result in
lower than expected increases of
digoxin concentrations.
Bepridil, Systemic Bepridil, Systemic Lidocaine, Caution is warranted and
Lidocaine, and Quinidine Quinidine: therapeutic drug concentration
Concentrations may be increased monitoring is recommended when
when co-administered with available.
lopinavir/ritonavir.
Antibiotics
Clarithromycin Clarithromycin: For patients with renal impairment
Moderate increases in (CrCL < 30 ml/min) dose reduction
clarithromycin AUC are expected of clarithromycin should be
due to CYP3A inhibition by considered (see section 4.4).
lopinavir/ritonavir. Caution should be exercised in
administering clarithromycin with
Kaletra to patients with impaired
hepatic or renal function.
Anticancer agents and kinase inhibitors
Abemaciclib Serum concentrations may be Co-administration of abemaciclib
increased due to CYP3A and Kaletra should be avoided. If
inhibition by ritonavir. this co-administration is judged
unavoidable, refer to the
abemaciclib SmPC for dosage
adjustment recommendations.
Monitor for ADRs related to
abemaciclib.
Apalutamide Apalutamide is a moderate to Decreased exposure of Kaletra may
strong CYP3A4 inducer and this result in potential loss of
may lead to a decreased exposure virological response.
of lopinavir/ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) abemaciclib (HOS-086209) lidocaine (HOS-108866) apalutamide (HOS-086212) bepridil (HOS-085612) quinidine (HOS-085593) digoxin (HOS-086172) lead (HOS-085592) clarithromycin (HOS-084517) amiodarone (HOS-085596) ranolazine (HOS-086141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 2a6dc58dcb1aed961671098b7774afc6ab5284838d7c3becb73533d81f884e22 · Zeichen 9077–14069 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 49–50
HOS-109006 · Präparat HOS-093083
49
Antiarrhythmics
Amiodarone, Amiodarone, Dronedarone: Concomitant administration of
Dronedarone Concentrations may be increased Kaletra and amiodarone or
due to CYP3A4 inhibition by dronedarone is contraindicated (see
lopinavir/ritonavir. section 4.3) as the risk of arrhythmias
or other serious adverse reactions
may be increased.
Digoxin Digoxin: Caution is warranted and therapeutic
Plasma concentrations may be drug monitoring of digoxin
increased due to P-glycoprotein concentrations, if available, is
inhibition by lopinavir/ritonavir. recommended in case of
The increased digoxin level may co-administration of Kaletra and
lessen over time as P-gp digoxin. Particular caution should be
induction develops. used when prescribing Kaletra in
patients taking digoxin as the acute
inhibitory effect of ritonavir on P-gp
is expected to significantly increase
digoxin levels. Initiation of digoxin
in patients already taking Kaletra is
likely to result in lower than expected
increases of digoxin concentrations.
Bepridil, Systemic Bepridil, Systemic Lidocaine, Caution is warranted and therapeutic
Lidocaine, and Quinidine: drug concentration monitoring is
Quinidine Concentrations may be increased recommended when available.
when co-administered with
lopinavir/ritonavir.
Antibiotics
Clarithromycin Clarithromycin: For patients with renal impairment
Moderate increases in (CrCL < 30 ml/min) dose reduction
clarithromycin AUC are expected of clarithromycin should be
due to CYP3A inhibition by considered (see section 4.4). Caution
lopinavir/ritonavir. should be exercised in administering
clarithromycin with Kaletra to
patients with impaired hepatic or
renal function.
Anticancer agents and kinase inhibitors
Abemaciclib Serum concentrations may be Co-administration of abemaciclib
increased due to CYP3A and Kaletra should be avoided. If
inhibition by ritonavir. this co-administration is judged
unavoidable, refer to the abemaciclib
SmPC for dosage adjustment
recommendations. Monitor for
ADRs related to abemaciclib.
Apalutamide Apalutamide is a moderate to Decreased exposure of Kaletra may
strong CYP3A4 inducer and this result in potential loss of virological
may lead to a decreased exposure response.
of lopinavir/ritonavir. In addition, co-administration of
apalutamide and Kaletra may lead to
Serum concentrations of serious adverse events including
apalutamide may be increased due seizure due to higher apalutamide
to CYP3A inhibition by levels. Concomitant use of Kaletra
lopinavir/ritonavir. with apalutamide is not
recommended.
Afatinib Afatinib: Caution should be exercised in
AUC: ↑ administering afatinib with Kaletra.
(Ritonavir 200 mg twice Cmax: ↑ Refer to the afatinib SmPC for
daily)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) abemaciclib (HOS-086209) lidocaine (HOS-108866) apalutamide (HOS-086212) bepridil (HOS-085612) quinidine (HOS-085593) digoxin (HOS-086172) lead (HOS-085592) afatinib (HOS-086207) clarithromycin (HOS-084517) amiodarone (HOS-085596)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage e2bfc1f119ab72d4142e3587fc0d81da448b5ce69a5003d6154afba7723f33c1 · Zeichen 9850–14882 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 84–85
HOS-109080 · Präparat HOS-093083
84
Fentanyl Fentanyl: Careful monitoring of adverse
Increased risk of side-effects effects (notably respiratory
(respiratory depression, sedation) depression but also sedation) is
due to higher plasma recommended when fentanyl is
concentrations because of concomitantly administered with
CYP3A4 inhibition by Kaletra.
lopinavir/ritonavir.
Antianginal
Ranolazine Due to CYP3A inhibition by The concomitant administration of
lopinavir/ritonavir, concentrations Kaletra and ranolazine is
of ranolazine are expected to contraindicated (see section 4.3).
increase.
Antiarrhythmics
Amiodarone, Amiodarone, Dronedarone: Concomitant administration of
Dronedarone Concentrations may be increased Kaletra and amiodarone or
due to CYP3A4 inhibition by dronedarone is contraindicated (see
lopinavir/ritonavir. section 4.3) as the risk of
arrhythmias or other serious adverse
reactions may be increased.
Digoxin Digoxin: Caution is warranted and
Plasma concentrations may be therapeutic drug monitoring of
increased due to P-glycoprotein digoxin concentrations, if available,
inhibition by lopinavir/ritonavir. is recommended in case of
The increased digoxin level may co-administration of Kaletra and
lessen over time as P-gp digoxin. Particular caution should
induction develops. be used when prescribing Kaletra in
patients taking digoxin as the acute
inhibitory effect of ritonavir on
P-gp is expected to significantly
increase digoxin levels. Initiation
of digoxin in patients already taking
Kaletra is likely to result in lower
than expected increases of digoxin
concentrations.
Bepridil, Systemic Bepridil, Systemic Lidocaine, Caution is warranted and
Lidocaine, and Quinidine: therapeutic drug concentration
Quinidine Concentrations may be increased monitoring is recommended when
when co-administered with available.
lopinavir/ritonavir.
Antibiotics
Clarithromycin Clarithromycin: For patients with renal impairment
Moderate increases in (CrCL < 30 ml/min) dose reduction
clarithromycin AUC are expected of clarithromycin should be
due to CYP3A inhibition by considered (see section 4.4).
lopinavir/ritonavir. Caution should be exercised in
administering clarithromycin with
Kaletra to patients with impaired
hepatic or renal function.
Anticancer agents and kinase inhibitors
Abemaciclib Serum concentrations may be Co-administration of abemaciclib
increased due to CYP3A and Kaletra should be avoided. If
inhibition by ritonavir. this co-administration is judged
unavoidable, refer to the
abemaciclib SmPC for dosage
adjustment recommendations.
Monitor for ADRs related to
abemaciclib.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) abemaciclib (HOS-086209) lidocaine (HOS-108866) bepridil (HOS-085612) quinidine (HOS-085593) digoxin (HOS-086172) clarithromycin (HOS-084517) fentanyl (HOS-086196) amiodarone (HOS-085596) ranolazine (HOS-086141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 441e910c1e6908f1a8725254649dcb0f97fdc57cf122c18523aa47225be733b2 · Zeichen 9035–13902 im Abschnitt
Wechselwirkungen · MicardisPlus
MicardisPlus 40 mg/12.5 mg tablets MicardisPlus 80 mg/12.5 mg tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-110361 · Präparat HOS-093371
Medicinal products affected by serum potassium disturbances
Periodic monitoring of serum potassium and ECG is recommended when telmisartan/HCTZ is
administered with medicinal products affected by serum potassium disturbances (e.g. digitalis
glycosides, antiarrhythmics) and the following torsades de pointes inducing medicinal products (which
include some antiarrhythmics), hypokalaemia being a predisposing factor to torsades de pointes.
- class Ia antiarrythmics (e.g. quinidine, hydroquinidine, disopyramide)
- class III antiarrythmics (e.g. amiodarone, sotalol, dofetilide, ibutilide)
- some antipsychotics (e.g. thioridazine, chlorpromazine, levomepromazine, trifluoperazine,
cyamemazine, sulpiride, sultopride, amisulpride, tiapride, pimozide, haloperidol, droperidol)
- others (e.g. bepridil, cisapride, diphemanil, erythromycin IV, halofantrin, mizolastin,
pentamidine, sparfloxacine, terfenadine, vincamine IV.)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sotalol (HOS-085597) sulpiride (HOS-087797) cisapride (HOS-085610) trifluoperazine (HOS-110368) bepridil (HOS-085612) droperidol (HOS-087801) dofetilide (HOS-085598) ibutilide (HOS-085599) quinidine (HOS-085593) chlorpromazine (HOS-087796) thioridazine (HOS-086281) cyamemazine (HOS-110369) hydroquinidine (HOS-085594) sultopride (HOS-085603) disopyramide (HOS-085595) diphemanil (HOS-085613) amisulpride (HOS-087798) pimozide (HOS-085600) erythromycin (HOS-084514) pentamidine (HOS-085605) haloperidol (HOS-085602) potassium (HOS-086929) amiodarone (HOS-085596) terfenadine (HOS-085607) tiapride (HOS-087799) vincamine (HOS-085611)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T09:30:00Z · SHA-256 33a880286f388c4977ad5f4024de04d276857e11506705f122fa64688952e4a1 · Passage 442b37ca411e99fcbe8bdcfa02416108b99469cada87c9a9fe88680684a58095 · Zeichen 1867–2815 im Abschnitt
Wechselwirkungen · MicardisPlus
MicardisPlus 80 mg/25 mg tablets · Abschnitt 4.5 · PDF-Seite 27
HOS-110434 · Präparat HOS-093371
Medicinal products affected by serum potassium disturbances
Periodic monitoring of serum potassium and ECG is recommended when telmisartan/HCTZ is
administered with medicinal products affected by serum potassium disturbances (e.g. digitalis
glycosides, antiarrhythmics) and the following torsades de pointes inducing medicinal products (which
include some antiarrhythmics), hypokalaemia being a predisposing factor to torsades de pointes.
- class Ia antiarrythmics (e.g. quinidine, hydroquinidine, disopyramide)
- class III antiarrythmics (e.g. amiodarone, sotalol, dofetilide, ibutilide)
- some antipsychotics (e.g. thioridazine, chlorpromazine, levomepromazine, trifluoperazine,
cyamemazine, sulpiride, sultopride, amisulpride, tiapride, pimozide, haloperidol, droperidol)
- others (e.g. bepridil, cisapride, diphemanil, erythromycin IV, halofantrin, mizolastin,
pentamidine, sparfloxacine, terfenadine, vincamine IV.)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sotalol (HOS-085597) sulpiride (HOS-087797) cisapride (HOS-085610) trifluoperazine (HOS-110368) bepridil (HOS-085612) droperidol (HOS-087801) dofetilide (HOS-085598) ibutilide (HOS-085599) quinidine (HOS-085593) chlorpromazine (HOS-087796) thioridazine (HOS-086281) cyamemazine (HOS-110369) hydroquinidine (HOS-085594) sultopride (HOS-085603) disopyramide (HOS-085595) diphemanil (HOS-085613) amisulpride (HOS-087798) pimozide (HOS-085600) erythromycin (HOS-084514) pentamidine (HOS-085605) haloperidol (HOS-085602) potassium (HOS-086929) amiodarone (HOS-085596) terfenadine (HOS-085607) tiapride (HOS-087799) vincamine (HOS-085611)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T09:30:00Z · SHA-256 33a880286f388c4977ad5f4024de04d276857e11506705f122fa64688952e4a1 · Passage 442b37ca411e99fcbe8bdcfa02416108b99469cada87c9a9fe88680684a58095 · Zeichen 1867–2815 im Abschnitt
Gegenanzeigen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.3 · PDF-Seite 4
HOS-112044 · Präparat HOS-093615
Co-administration with medicinal products that are substrates of the CYP3A4 isoform of cytochrome
P450 and have narrow therapeutic windows (e.g., quetiapine, lurasidone, alfuzosin, astemizole,
terfenadine, cisapride, pimozide, quinidine, bepridil, triazolam, midazolam administered orally (for
caution on parenterally administered midazolam, see section 4.5), lomitapide, and ergot alkaloids,
particularly, ergotamine, dihydroergotamine, ergonovine, methylergonovine) (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) alfuzosin (HOS-086139) methylergonovine (HOS-086155) cisapride (HOS-085610) lomitapide (HOS-086160) bepridil (HOS-085612) quinidine (HOS-085593) ergot alkaloids (HOS-108807) pimozide (HOS-085600) astemizole (HOS-085608) ergotamine (HOS-086154) terfenadine (HOS-085607) lurasidone (HOS-086148) ergonovine (HOS-086153) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 7b7b0f048824fcb784b546989cbc26fbf98af81b02e5d50ce08dc589e2545d88 · Zeichen 636–1122 im Abschnitt
Gegenanzeigen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.3 · PDF-Seite 40
HOS-112152 · Präparat HOS-093615
Co-administration with medicinal products that are substrates of the CYP3A4 isoform of cytochrome
P450 and have narrow therapeutic windows (e.g., quetiapine, alfuzosin, astemizole, terfenadine,
cisapride, pimozide, quinidine, lurasidone, bepridil, triazolam, midazolam administered orally (for
caution on parenterally administered midazolam, see section 4.5), lomitapide and ergot alkaloids,
particularly, ergotamine, dihydroergotamine, ergonovine, methylergonovine) (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) alfuzosin (HOS-086139) methylergonovine (HOS-086155) cisapride (HOS-085610) lomitapide (HOS-086160) bepridil (HOS-085612) quinidine (HOS-085593) ergot alkaloids (HOS-108807) pimozide (HOS-085600) astemizole (HOS-085608) ergotamine (HOS-086154) terfenadine (HOS-085607) lurasidone (HOS-086148) ergonovine (HOS-086153) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage e442989da36600ebf7f8db27c93ddf7cb3e10a213eeefa38bb99d1990671ccee · Zeichen 495–980 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 8
HOS-112050 · Präparat HOS-093615
Atazanavir is metabolised in the liver through CYP3A4. It inhibits CYP3A4. Therefore, REYATAZ is
contraindicated with medicinal products that are substrates of CYP3A4 and have a narrow therapeutic
index: quetiapine, lurasidone, alfuzosin, astemizole, terfenadine, cisapride, pimozide, quinidine,
bepridil, triazolam, orally administered midazolam, lomitapide, and ergot alkaloids, particularly
ergotamine and dihydroergotamine (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) alfuzosin (HOS-086139) cisapride (HOS-085610) lomitapide (HOS-086160) bepridil (HOS-085612) quinidine (HOS-085593) ergot alkaloids (HOS-108807) pimozide (HOS-085600) astemizole (HOS-085608) ergotamine (HOS-086154) terfenadine (HOS-085607) lurasidone (HOS-086148) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 85781e83a9b10bfbdd236ee812040730eb3a9b3f74e06aebc98fed6a6305ec35 · Zeichen 315–760 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 19–20
HOS-112103 · Präparat HOS-093615
19
Medicinal products by Interaction Recommendations concerning co-
therapeutic area administration
Calcium channel blockers
Bepridil REYATAZ should not be used in Co-administration with bepridil is
combination with medicinal products that contraindicated (see section 4.3)
are substrates of CYP3A4 and have a
narrow therapeutic index.
Diltiazem 180 mg once daily Diltiazem AUC: ↑125% (↑109% ↑141%) An initial dose reduction of
(atazanavir 400 mg once daily) Diltiazem Cmax: ↑98% (↑78% ↑119%) diltiazem by 50% is recommended,
Diltiazem Cmin: ↑142% (↑114% ↑173%) with subsequent titration as needed
and ECG monitoring.
Desacetyl-diltiazem AUC: ↑165% (↑145%
↑187%)
Desacetyl-diltiazem Cmax: ↑172% (↑144%
↑203%)
Desacetyl-diltiazem Cmin: ↑121% (↑102%
↑142%)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) bepridil (HOS-085612) calcium (HOS-085615)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage a5938ef1523f856eb59b74422c7cfaea01c48399a19f2b7a8ea958d4d8e50ef3 · Zeichen 51161–52517 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 44
HOS-112157 · Präparat HOS-093615
Atazanavir is metabolised in the liver through CYP3A4. It inhibits CYP3A4. Therefore, REYATAZ
with ritonavir is contraindicated with medicinal products that are substrates of CYP3A4 and have a
narrow therapeutic index: quetiapine, lurasidone, alfuzosin, astemizole, terfenadine, cisapride,
pimozide, quinidine, bepridil, triazolam, orally administered midazolam, lomitapide, and ergot
alkaloids, particularly ergotamine and dihydroergotamine (see section 4.3). Co-administration of
REYATAZ with grazoprevir-containing products, including elbasvir/grazoprevir fixed-dose
combination is contraindicated because of the increase in grazoprevir and elbasvir plasma
concentrations and potential for the increase in risk of ALT elevations associated with increased
grazoprevir concentrations (see section 4.3). Co-administration of REYATAZ with
glecaprevir/pibrentasvir fixed-dose combination is contraindicated because of the potential increase in
the risk of ALT elevations due to a significant increase in glecapreir and pibrentasvir plasma
concentrations (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) elbasvir (HOS-108814) alfuzosin (HOS-086139) cisapride (HOS-085610) pibrentasvir (HOS-086298) lomitapide (HOS-086160) bepridil (HOS-085612) quinidine (HOS-085593) glecaprevir (HOS-086297) grazoprevir (HOS-108815) pimozide (HOS-085600) astemizole (HOS-085608) ergotamine (HOS-086154) ritonavir (HOS-084521) terfenadine (HOS-085607) lurasidone (HOS-086148) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 8c472f02d161fbf877b321685a02acd6721db094612098433562a9a244834b35 · Zeichen 315–1385 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 54–55
HOS-112192 · Präparat HOS-093615
54
Medicinal products by Interaction Recommendations
therapeutic area concerning co-administration
Ivosidenib The mechanism of interaction is CYP3A4 Co-administration of
inhibition by atazanavir and/or ritonavir. ivosidenib with REYATAZ
(with or without ritonavir) is
contraindicated due to potential
for loss of virologic response,
development of resistance,
increase in ivosidenib plasma
concentration and subsequent
risk of serious adverse events
such as QT interval
prolongation (see section 4.3).
Irinotecan Atazanavir inhibits UGT and may interfere If REYATAZ is co-
with the metabolism of irinotecan, resulting administered with irinotecan,
in increased irinotecan toxicities. patients should be closely
monitored for adverse events
related to irinotecan.
Immunosuppressants
Cyclosporin Concentrations of these More frequent therapeutic
Tacrolimus immunosuppressants may be increased concentration monitoring of
Sirolimus when co-administered with REYATAZ due these medicinal products is
to CYP3A4 inhibition. recommended until plasma
levels have been stabilised.
CARDIOVASCULAR AGENTS
Antiarrhythmics
Amiodarone, Concentrations of these antiarrhythmics Caution is warranted and
Systemic lidocaine, may be increased when co-administered therapeutic concentration
Quinidine with REYATAZ. The mechanism of monitoring is recommended
amiodarone or systemic when available. The
lidocaine/atazanavir interaction is CYP3A concomitant use of quinidine is
inhibition. Quinidine has a narrow contraindicated (see
therapeutic window and is contraindicated section 4.3).
due to potential inhibition of CYP3A by
REYATAZ.
Calcium channel blockers
Bepridil REYATAZ should not be used in Co-administration with
combination with medicinal products that bepridil is contraindicated (see
are substrates of CYP3A4 and have a section 4.3)
narrow therapeutic index.
Diltiazem 180 mg once daily Diltiazem AUC: ↑125% (↑109% ↑141%) An initial dose reduction of
(atazanavir 400 mg once daily) Diltiazem Cmax: ↑98% (↑78% ↑119%) diltiazem by 50% is
Diltiazem Cmin: ↑142% (↑114% ↑173%) recommended, with subsequent
titration as needed and ECG
Desacetyl-diltiazem AUC: ↑165% (↑145% monitoring.
↑187%)
Desacetyl-diltiazem Cmax: ↑172% (↑144%
↑203%)
Desacetyl-diltiazem Cmin: ↑121% (↑102%
↑142%)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) lidocaine (HOS-108866) bepridil (HOS-085612) quinidine (HOS-085593) calcium (HOS-085615) tacrolimus (HOS-085202) ivosidenib (HOS-112046) sirolimus (HOS-085172) ritonavir (HOS-084521) amiodarone (HOS-085596) irinotecan (HOS-112102)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 8e30f6119b7915e33c652e423a799b6a4590263851081846f12e942eec018b80 · Zeichen 49648–54131 im Abschnitt
Wechselwirkungen · Procoralan
Procoralan 5 mg film-coated tablets Procoralan 7.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-113847 · Präparat HOS-093985
QT prolonging medicinal products
- Cardiovascular QT prolonging medicinal products (e.g. quinidine, disopyramide, bepridil, sotalol,
ibutilide, amiodarone).
- Non cardiovascular QT prolonging medicinal products (e.g. pimozide, ziprasidone, sertindole,
mefloquine, halofantrine, pentamidine, cisapride, intravenous erythromycin).
The concomitant use of cardiovascular and non cardiovascular QT prolonging medicinal products with
ivabradine should be avoided since QT prolongation may be exacerbated by heart rate reduction. If the
combination appears necessary, close cardiac monitoring is needed (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) sotalol (HOS-085597) cisapride (HOS-085610) ziprasidone (HOS-113848) bepridil (HOS-085612) halofantrine (HOS-085606) ibutilide (HOS-085599) quinidine (HOS-085593) disopyramide (HOS-085595) pimozide (HOS-085600) erythromycin (HOS-084514) pentamidine (HOS-085605) amiodarone (HOS-085596) mefloquine (HOS-113850)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T17:49:00Z · SHA-256 603a04f5264f2cd02119b9fdddd8869a5b599fbe491c4482b048613e56f12c88 · Passage a7040ace52217c8fd344c8e8b0b2e3abb9c3576c728b6258f0f6706533737ea4 · Zeichen 63–683 im Abschnitt
Wechselwirkungen · Corlentor
Corlentor 5 mg film-coated tablets Corlentor 7.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-113885 · Präparat HOS-093993
QT prolonging medicinal products
- Cardiovascular QT prolonging medicinal products (e.g. quinidine, disopyramide, bepridil, sotalol,
ibutilide, amiodarone).
- Non cardiovascular QT prolonging medicinal products (e.g. pimozide, ziprasidone, sertindole,
mefloquine, halofantrine, pentamidine, cisapride, intravenous erythromycin).
The concomitant use of cardiovascular and non cardiovascular QT prolonging medicinal products with
ivabradine should be avoided since QT prolongation may be exacerbated by heart rate reduction. If the
combination appears necessary, close cardiac monitoring is needed (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) sotalol (HOS-085597) cisapride (HOS-085610) ziprasidone (HOS-113848) bepridil (HOS-085612) halofantrine (HOS-085606) ibutilide (HOS-085599) quinidine (HOS-085593) disopyramide (HOS-085595) pimozide (HOS-085600) erythromycin (HOS-084514) pentamidine (HOS-085605) amiodarone (HOS-085596) mefloquine (HOS-113850)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T17:03:00Z · SHA-256 d87e68351dedcde32d83ee33c2f0d9205f341c44bb5b4d122f4a04ffba50a0e0 · Passage a7040ace52217c8fd344c8e8b0b2e3abb9c3576c728b6258f0f6706533737ea4 · Zeichen 63–683 im Abschnitt
Gegenanzeigen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.3 · PDF-Seite 4
HOS-114797 · Präparat HOS-094169
Co-administration of Aptivus with low dose ritonavir, with active substances that are highly dependent
on CYP3A for clearance, and for which elevated plasma concentrations are associated with serious
and/or life-threatening events. These active substances include antiarrhythmics (such as amiodarone,
bepridil, quinidine), antihistamines (such as astemizole, terfenadine), ergot derivatives (such as
dihydroergotamine, ergonovine, ergotamine, methylergonovine), gastrointestinal motility agents (such
as cisapride), antipsychotics (such as pimozide, sertindole, quetiapine, lurasidone), sedatives/hypnotics
(such as orally administered midazolam and triazolam) and HMG-CoA reductase inhibitors (such as
simvastatin and lovastatin) (see section 4.5). Also the use of the alpha-1 adrenoceptor antagonist
alfuzosin, and sildenafil when used for the treatment of pulmonary arterial hypertension. In addition,
co-administration of Aptivus with low dose ritonavir, and medicinal products that are highly
dependent on CYP2D6 for clearance, such as the antiarrhythmics flecainide, propafenone and
metoprolol given in heart failure (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) quetiapine (HOS-086150) alfuzosin (HOS-086139) methylergonovine (HOS-086155) propafenone (HOS-084530) cisapride (HOS-085610) lovastatin (HOS-086157) flecainide (HOS-086203) bepridil (HOS-085612) simvastatin (HOS-086158) quinidine (HOS-085593) pimozide (HOS-085600) astemizole (HOS-085608) sildenafil (HOS-086162) ergotamine (HOS-086154) ritonavir (HOS-084521) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ergonovine (HOS-086153) metoprolol (HOS-090094) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 899ebcf3829943bae5ad39416161803c04f5d7f21f78b5a86a8cc0fb492896e8 · Zeichen 519–1660 im Abschnitt
Wechselwirkungen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 19–20
HOS-114844 · Präparat HOS-094169
19
H2-receptor antagonists
No interaction study No data are available for An increase in gastric pH that
performed H2-receptor antagonists in may result from H2-receptor
combination with tipranavir and antagonist therapy is not expected
low dose ritonavir. to have an impact on tipranavir
plasma concentrations.
Antiarrhythmics
Amiodarone Based on theoretical The concomitant use of Aptivus,
Bepridil considerations, tipranavir, co- co-administered with low dose
Quinidine administered with low dose ritonavir, with amiodarone,
No interaction study ritonavir, is expected to increase bepridil or quinidine is
performed amiodarone, bepridil and contraindicated due to potential
quinidine concentrations. serious and/or life threatening
events (see section 4.3)
Inhibition of CYP 3A4 by
tipranavir/r
Flecainide Based on theoretical The concomitant use of Aptivus,
Propafenone considerations, tipranavir, co- co-administered with low dose
Metoprolol (given in heart administered with low dose ritonavir, with flecainide,
failure) ritonavir, is expected to increase propafenone or metoprolol is
No interaction study flecainide, propafenone and contraindicated (see section 4.3)
performed metoprolol concentrations.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propafenone (HOS-084530) flecainide (HOS-086203) bepridil (HOS-085612) quinidine (HOS-085593) ritonavir (HOS-084521) amiodarone (HOS-085596) metoprolol (HOS-090094)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 6aa9e00d4b58261863af53d4fabbddef6456a645d8623cbe7ba0ff2c874fe543 · Zeichen 48623–50469 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.